Inherited thrombophilia: Part 2

Thrombosis and Haemostasis

Volumn 76, Issue 6, 1996, Pages 824-834

  Lane, David A ^a,l   Mannucci, Pier M ^b   Bauer, Kenneth A ^c   Bertina, Rogier M ^d   Bochkov, Nikolay P ^e   Boulyjenkov, Victor ^f   Chandy, Mammen ^g   Dahlbäck, Björn ^h   Ginter, E K ⁱ   Miletich, Joseph P ^j   Rosendaal, Frits R ^d   Seligsohn, Uri ^k  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g CHRISTIAN MEDICAL COLLEGE   (India)

^h LUND UNIVERSITY   (Sweden)

ⁱ Institute of Genetics   (Russian Federation)

^j WASHINGTON UNIVERSITY   (United States)

^k The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; COUMARIN; FIBRINOLYTIC AGENT; HEPARIN; PROTEIN C; WARFARIN;

CLINICAL FEATURE; DEVELOPING COUNTRY; DIAGNOSTIC TEST; FAMILIAL DISEASE; FIBRINOLYTIC THERAPY; FULMINATING PURPURA; GENE MUTATION; HUMAN; LABORATORY DIAGNOSIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEWBORN; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; SCREENING TEST; SKIN NECROSIS; THROMBOPHILIA;

EID: 0347516652     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650673     Document Type: Review

References (106)

1. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
2. Malm J, Aurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
3. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
4. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-71.
5. Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61.
6. Zöller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be pheno-typic variants of the same genetic disease. Blood 1995; 85: 3524-31.
7. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
8. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-7.
9. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11.
10. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7.
11. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
12. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
13. Rosen S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group. Thromb Haemost 1994; 72: 255-60.
14. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
15. Shizuka R, Kanda T, Amagai H, Kobayashi I. False-positive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with platelets. Thromb Res 1995; 78: 189-90.
16. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-3.
17. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
18. Trossaert M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73: 163-4.
19. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
20. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
21. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg 506 Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
22. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
23. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg 506 of factor V. Lancet 1994; 343: 1535-6.
24. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
25. Gandrille S, Alhenc Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 to Gln mutation. Blood Coag Fibrinolysis 1995; 6: 245-8.
26. Briët E, Broekmans AW. Hereditary protein S deficiency. In: Protein C and related proteins. Bertina RM (eds). Churchill Livingstone, Edinburgh 1988; pp 203.
27. Broekmans AW, Conard J. Hereditary protein C deficiency. In: Protein C and related proteins. Bertina RM (eds). Churchill Livingstone, Edinburgh 1988; pp 160.
28. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116: 754-61.
29. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-8.
30. Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 1994; 71: 15-8.
31. Martinelli I, Faioni EM, Monzani ML, Mannucci PM. Inherited resistance to activated protein C (APC): clinical and laboratory features. Blood 1994; 84 supp 1: 84a.
32. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
33. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
34. van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21.
35. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT HI, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-20.
36. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 71: 799-800.
37. De Stefano V, Mastrangelo S, Paciaroni K, Ireland H, Lane DA, Scirpa P, Bizzi B, Leone G. Thrombotic risk during pregnancy and puerperium in women with APC-resistance. Effective subcutaneous heparin in prophylaxis in a pregnant patient. Thromb Haemost 1995; 74: 793-4.
38. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71: 548-52.
39. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
40. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094.
41. Chowdhury V, Lane DA, Auberger K, Gandenberger-Bachem S, Pabinger I, Olds RJ, Thein SL. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
42. Hakten M, Deniz U, Ozbag G, Ulutin ON. Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of ATIII. In: Thrombosis and haemorrhagic disorders. Senzinger H, Vinazzer H (eds). Schmitt and Meyer GmbH, Wurzberg 1989; pp 177-81.
43. Tripodi A, Franchi F, Krachmalnicoff A, Mannucci PM. Asymptomatic homozygous protein C deficiency. Acta Haematol 1990; 83: 152-5.
44. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a new-born infant. Lancet 1983; 2: 1165-8.
45. Marlar RA, Montgomery RR, Madden RM. Homozygous protein C deficiency. In: Protein C and related proteins. Bertina RM (eds). Churchill Livingstone, Edinburgh 1988; pp 182.
46. Sharon C, Tirindelli MC, Mannucci PM, Tripodi A, Mariani G. Homozygous protein C deficiency with moderately severe clinical symptoms. Thromb Res 1986; 41: 483-8.
47. Mahasandana C, Suvatte V, Marlar RA, Manco Johnson MJ, Jacobson LJ, Hathaway WE. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335: 61-2.
48. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
49. Holm J, Zoller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C [letter]. Lancet 1994; 344: 952-3.
50. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N Engl J Med 1995; 332: 912-7.
51. Cruickshank MK, Levine MN, Hirsh J, Roberts RS, Siquenza M. A standard heparin monogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-7.
52. Raschke RA, Reilly BM, Guidry JR, Fontana RR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomo-gram. Ann Intern Med 1993; 199: 874-81.
53. Brill-Edwards P, Ginsberg JS, Johnstone M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.
54. Bjornsson JD, Nash PV. Variability in heparin sensitivity of APTT reagents. Am J Clin Path 1986; 86: 199-204.
55. Hull RD, Raskob GE, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial management of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4.
56. Schulman S, Tengbom L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-6.
57. Hoffman DL. Purification and large scale preparation of antithrombin III. Am J Med 1989; 87: 23S-26S.
58. Menache D, O'Malley JP, Schorr JB, Wagner B, Williams C, Alving BM, Ballard JO, Goodnight SH, Hathaway WE, Hultin MB. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990; 75: 33-39.
59. Mannucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982; 50: 33-9.
60. Winter JH. Transfusion studies in patients with familial antithrombin deficiency: half disappearance time of infused antithrombin III and influence of such infusions on platelet life span. Br J Haematol 1981; 49: 449-53.
61. Brandt P. Observations during treatment of antithrombin III deficient women in heparin and antithrombin III during pregnancy, parturition, and abortion. Thromb Res 1981; 22: 15-24.
62. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical experiences with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989; 87: 53S-60S.
63. Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104: 659-60.
64. De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70: 247-9.
65. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lators G, Nicol P. A comparison of six weeks with six months of oral anticoagulation after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
66. Levine MN, Hirsh J, Gent M. Optimal duration of oral anticoagulant therapy: a randomised trial comparing four weeks with three months of warfarin in patients with proximal deep venous thrombosis. Thromb Haemost 1995; 74: 606-11.
67. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
68. Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-85.
69. Hirsh J, Prins MH, Samama M. Approach to the thrombophilic patient. In: Hemostasis and Thrombosis: basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Salzman EW (eds). Lippincott, Philadelphia 1994; pp 1543-61.
70. Bauer KA. Hypercoagulable states. In: Hematology: basic principles and clinical practice. Hoffman R, Benz EJ, Shattil SJ (eds). Churchill Livingstone, New York 1995; pp 1781-95.
71. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87 (suppl 3B): 34S-38S.
72. Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Ann Rev Med 1989; 40: 79-86.
73. Iturbe-Alessio I, Foneseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-3.
74. Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983; 49: 251.
75. Broekmans AW, Teepe RGC, van der Meer FJM, Briët E, Bertina RM. Protein C (PC) and coumarin-induced skin necrosis. Thromb Res 1986; 6: 137 (abstract).
76. Friedman KD, Marlar RA, Houson JG, Montgomery RR. Warfarin-induced skin necrosis in a patient with protein S deficiency. Blood 1986; 68 (suppl): 333a (abstract).
77. Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993; 129: 753-6.
78. Estelles A, Garcia Plaza I, Dasi A, Aznar J, Duart M, Sanz G, Perez Requejo JL, Espana F, Jimenez C, Abeledo G. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost 1984; 52: 53-6.
79. Sills RH, Marlar RA. Montgomery RR, Deshpande GN, Humbert JR. Severe homozygous protein C deficiency. J Pediatr 1984; 105: 409-13.
80. Yuen P, Cheung A, Lin HJ, Ho F, Mimuro J, Yoshida N, Aoki N. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics 1986; 77: 670-6.
81. Comp PC, Nixon RR, Esmon CT. Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex. Blood 1984; 63: 15-21.
82. Vigano S, Mannucci PM, Solinas S, Bottasso B, Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57: 213-20.
83. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565-8.
84. Peters C, Casella JF, Marlar RA, Montgomery RR, Zinkham WH. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics 1988; 81: 272-6.
85. Garcia Plaza I, Jimenez Astorga C, Borrego D, Marty ML. Coumarin prophylaxis for fulminant purpura syndrome due to homozygous protein C deficiency. Lancet 1985; 1: 634-5.
86. Hartman KR, Manco Johnson M, Rawlings JS, Bower DJ, Marlar RA. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol 1989; 11: 395-401.
87. Casella JF, Lewis JH, Bontempo FA, Zitelli BJ, Markel H, Starzl TE. Successful treatment of homozygous protein C deficiency by hepatic transplantation. Lancet 1988; 1: 435-8.
88. Pegelow CH, Ledford M, Young JN, Zilleruelo G. Severe protein S deficiency in a newborn. Pediatrics 1992; 89: 674-6.
89. Mahasandana C, Suvatte V, Chuansumrit A, Marlar RA, Manco Johnson MJ, Jacobson LJ, Hathaway WE. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117: 750-3.
90. Mibashan RS, Millar DS, Rodeck CH, Nicolaides KH, Berger A, Seligsohn U. Prenatal diagnosis of hereditary protein C deficiency [letter]. N Engl J Med 1985; 313: 1607.
91. Melissari E, Nicolaides KH, Scully MF, Kakkar VV. Protein S and C4b-binding protein in fetal and neonatal blood. Br J Haematol 1988; 70: 199-203.
92. Moalic P, Gruel Y, Body G, Foloppe P, Delahousse B, Leroy J. Levels and plasma distribution of free and C4b-BP-bound protein S in human fetuses and full-term newborns. Thromb Res 1988; 49: 471-80.
93. Gandrille S, Goossens M, Aiach M. Scanning method to establish the molecular basis of protein C deficiencies. Hum Mutat 1994; 4: 20-30.
94. Gandrille S, Borgel D, Eschwege Gufflet V, Aillaud M, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sie P, Toulon P, Aiach M. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 1995; 85: 130-8.
95. Millar DS, Allgrove J, Rodeck C, Kakkar VV, Cooper DN. A homozygous deletion/insertion mutation in the protein C (PROC) gene causing neonatal Purpura fulminans: prenatal diagnosis in an at-risk pregnancy. Blood Coagul Fibrinolysis 1994; 5: 647-9.
96. Lane DA, Auberger K, Ireland H, Roscher AA, Thein SL. Prenatal diagnosis in combined antithrombin and factor V mutation. Brit J Haematol 1996; 94: 753-5.
97. Formstone CJ, Yoke J, Tuddenham EGD, Jenkins E, Clark J, Layton M, Nicolaides K, Kakkar VV, Cooper DC. Prenatal exclusion of severe protein S deficiency by indirect RFLP analysis. Thromb Haemostas 1993; 69: 931.
98. Cunningham IGE, Young NK. The incidence of post operative deep vein thrombosis in Malaysia. Br J Surg 1974; 61: 482.
99. Osime U. Incidence of post operative deep vein thrombosis in Nigerians using 125 I-labelled fibrinogen. Br Med J 1978; 2: 1607.
100. Nandi P, Wong KP, Wei WI, Ngan H, Ong GB. Incidence of postoperative deep vein thrombosis in Hong Kong Chinese. Br J Surg 1980; 67: 251-3.
101. Hassan MA, Rahman EA, Rahman IA. Prostatectomy and deep vein thrombosis in Sudanese patients. Br J Surg 1974; 61: 650.
102. Chumnijarakij T, Poshyachinda V. Post operative thrombosis in Thai women. Lancet 1975; 1: 1357.
103. Awidi AS, Abu Khalaf M, Herzallah U, Abu Rajab A, Shannak MM, Abu Obeid T, al Taher I, Anshasi B. Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. Am J Hematol 1993; 44: 95-100.
104. Liu HW, Kwong YL, Bourke C, Lam CK, Lie AK, Wei D, Chan LC. High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 1994; 71: 416-9.
105. Chafa O, Fischer AM, Sternberg C, Meriane F, Millien C, Benabadji M. The relative frequency of inherited inhibitor deficiency among 93 young patients with thrombophilia in Algeria [letter]. Blood Coagul Fibrinolysis 1993; 4: 639-40.
106. Martinez HR, Rangel Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults. Stroke 1993; 24: 19-25.